Ernexa Therapeutics (ERNA) Net Margin (2016 - 2024)
Historic Net Margin for Ernexa Therapeutics (ERNA) over the last 14 years, with Q4 2024 value amounting to 30352.63%.
- Ernexa Therapeutics' Net Margin fell 177791600.0% to 30352.63% in Q4 2024 from the same period last year, while for Sep 2025 it was 96610.53%, marking a year-over-year decrease of 894757600.0%. This contributed to the annual value of 7425.83% for FY2024, which is 142581700.0% up from last year.
- According to the latest figures from Q4 2024, Ernexa Therapeutics' Net Margin is 30352.63%, which was down 177791600.0% from 5462.83% recorded in Q3 2024.
- Ernexa Therapeutics' Net Margin's 5-year high stood at 24328.57% during Q2 2022, with a 5-year trough of 30352.63% in Q4 2024.
- In the last 4 years, Ernexa Therapeutics' Net Margin had a median value of 2866.1% in 2020 and averaged 4985.08%.
- Per our database at Business Quant, Ernexa Therapeutics' Net Margin crashed by -225645100bps in 2023 and then skyrocketed by 54999100bps in 2024.
- Over the past 4 years, Ernexa Therapeutics' Net Margin (Quarter) stood at 217.96% in 2020, then surged by 11262bps to 24328.57% in 2022, then tumbled by -152bps to 12573.47% in 2023, then crashed by -141bps to 30352.63% in 2024.
- Its Net Margin stands at 30352.63% for Q4 2024, versus 5462.83% for Q3 2024 and 11780.85% for Q2 2024.